Aldoxorubicin: Interim Phase Ib data

Interim data from 7 evaluable patients in an open-label, dose-escalation Phase Ib trial showed that IV aldoxorubicin on day 1 of a 28-day cycle plus ifosfamide/ mesna led to a complete tumor response ...